English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS ER

Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 million, and net loss was $38.1 million. The company updated its 2024 guidance, projecting software revenue growth of 8-13% and drug discovery revenue between $20-30 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
6673 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    6107Followers
    70Following
    65KVisitors
    Follow